IFP Advisors Inc Grows Stock Position in GSK plc (NYSE:GSK)

IFP Advisors Inc lifted its stake in shares of GSK plc (NYSE:GSK) by 113.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,392 shares of the pharmaceutical company’s stock after purchasing an additional 6,578 shares during the quarter. IFP Advisors Inc’s holdings in GSK were worth $419,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. FMR LLC grew its holdings in GSK by 8.3% during the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after acquiring an additional 2,224,345 shares during the period. Fisher Asset Management LLC grew its holdings in GSK by 4.9% during the third quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock worth $759,425,000 after acquiring an additional 870,449 shares during the period. Clifford Capital Partners LLC grew its holdings in GSK by 14.3% during the third quarter. Clifford Capital Partners LLC now owns 409,669 shares of the pharmaceutical company’s stock worth $16,747,000 after acquiring an additional 51,378 shares during the period. Cerity Partners LLC grew its holdings in GSK by 61.8% during the third quarter. Cerity Partners LLC now owns 433,628 shares of the pharmaceutical company’s stock worth $17,728,000 after acquiring an additional 165,556 shares during the period. Finally, Natixis Advisors LLC grew its holdings in GSK by 20.0% during the third quarter. Natixis Advisors LLC now owns 500,495 shares of the pharmaceutical company’s stock worth $20,460,000 after acquiring an additional 83,433 shares during the period. Hedge funds and other institutional investors own 15.74% of the company’s stock.

GSK Stock Up 0.8 %

GSK opened at $37.59 on Friday. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. The firm has a market cap of $77.90 billion, a P/E ratio of 23.64, a PEG ratio of 1.12 and a beta of 0.64. GSK plc has a 52 week low of $31.72 and a 52 week high of $45.92. The business’s fifty day simple moving average is $34.99 and its 200 day simple moving average is $37.26.

GSK (NYSE:GSK) last posted its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. As a group, equities research analysts anticipate that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be paid a dividend of $0.3932 per share. The ex-dividend date of this dividend is Friday, February 21st. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.18%. This is a positive change from GSK’s previous quarterly dividend of $0.39. GSK’s dividend payout ratio (DPR) is presently 98.74%.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on GSK shares. Jefferies Financial Group lowered GSK from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $53.00 to $39.50 in a report on Tuesday, November 12th. StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, February 7th. Morgan Stanley assumed coverage on GSK in a report on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Finally, Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Seven equities research analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.